PDI at hold by Jefferies

PDI, Inc. was reiterated at a hold rating and a $12 price target by Jefferies & Co., Inc. analyst David Windley while Jefferies looks for clarity on PDI's discussions with AstraZeneca. The discussions center on the status of AstraZeneca's fee-for-service contract. PDI remains below Jefferies' target in the foreseeable future. Shares of the Saddle River, N.J., biopharmaceutical company were down $2.28, or 15.97%, at $12.00 on volume of 337,070 shares versus the three-month running average of 72,607 shares. (Nasdaq: PDII)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.